Protagenic Therapeutics, Inc.
PTIX
$0.218
-$0.0001-0.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -10.49% | -43.87% | -85.38% | -106.31% | -40.64% |
| Total Depreciation and Amortization | 78.72% | 3,925.00% | 26,500.00% | 40,600.00% | -- |
| Total Amortization of Deferred Charges | -- | -89.91% | -64.69% | -44.23% | -22.63% |
| Total Other Non-Cash Items | -39.02% | 56.23% | 36.92% | 53.09% | 42.42% |
| Change in Net Operating Assets | 508.38% | -205.19% | 156.66% | -1,531.80% | -121.20% |
| Cash from Operations | -13.85% | -65.73% | -91.30% | -157.94% | -85.76% |
| Capital Expenditure | -- | -63.19% | -8,222.22% | -8,222.22% | -8,222.22% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -43.09% | 90.48% | 139.78% | 283.10% | 208.06% |
| Cash from Investing | -41.31% | 91.07% | 133.79% | 273.71% | 199.03% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -30.00% | -98.42% | -99.73% | -99.01% | -98.59% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -48.67% | 18,150.00% | 691.61% | 301.78% | 429.15% |